

Patient Organisation disclosure template 2025						
PO name	Country	Types of the support or services provided	Description of the support or services 1	Monetary value of financial support and of invoiced costs	Non-monetary benefit for PO 2	Fees for services paid
Arthritis Ireland	Ireland	Financial support	Johnson and Johnson Innovative Medicine provided €10,000 to support Arthritis Ireland's STEPS Clinical Referral Programme	10,000.00	0	0
CLL Ireland	Ireland	Financial support	Johnson and Johnson Innovative Medicine provided funding to CLL Ireland to support their annual National Patient Day	6,000.00	0	0
IPPOSI	Ireland	Financial support	J&J provided €10,000 for 2025 IPPOSI activities	10,000.00	0	0
IPPOSI	Ireland	Financial support	J&J Ireland provided €10,000 to support IPPOSI projects in 2026	10,000.00	0	0
Irish Lung Cancer Community	Ireland	Financial support	Johnson & Johnson provided support for the Irish Lung Cancer Community's patient information day.	500.00	0	0
Irish Soc Colitis/Crohns Dis	Ireland	Financial support	J&J provided €10,000 to support CCI activities in 2025, including the development and distribution of their membership magazine and promotion of patient podcast series	10,000.00	0	0
Multiple Myeloma Ireland	Ireland	Financial support	J&J provided funding to Multiple Myeloma Ireland to support its HCP research grants.	10,000.00	0	0
PHA Ireland	Ireland	Financial support	Johnson & Johnson Innovative Medicine provided funding to PHA Ireland to support an AGM meeting, patient support group meetings, education materials, website updates and social media outreach	13,000.00		
Retina International	Ireland	Financial support	Support for Mental health study, community advisory boards and continuous education programmes	120,000.00	0	0
Retina International	Ireland	Financial support	Payment in support the ongoing work of Retina International's Committee of Retinal Experts (CORE) to identify and address roadblocks to the diagnosis, care, and treatment of retinal diseases.	42,500.00	0	0
Retina International	Ireland	Financial support	Sponsorship of Community literacy and Continuous Education Programme (CEP)	50,000.00	0	0
Irish Lung Cancer Community Ltd	Ireland	Contracted services	Payment to ILCC representatives to speak at Patient Connect event in Cork including transport cost for speaker to the value of €166	0	166	880.00
Sarah Jennifer Knott Foundation	Ireland	Contracted services	2024 - Precision Medicine Pathway PAG Ad Board - SJK Foundation	0	0	660.00

Johnson & Johnson: Methodological note for Healthcare Professionals/Healthcare Organisations and Patient Organisations disclosure 2025

Data year: 2025

Year of publication: 2026

Country: Ireland

The information below describes the methodology that Janssen Sciences Ireland UC, pharmaceutical companies of Johnson & Johnson (J&J) has applied to disclose the Transfers of Value (ToV) made to Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and Patient Organisations (POs) in the submission to the Irish Pharmaceutical Healthcare Association (IPHA).

Contents

1. Definitions	2
1.1 Recipients.....	2
1.2 Kind of ToVs	3
2. Disclosure's Scope.....	4
2.1 Products concerned.....	4
2.2 Company concerned	4
2.3 Excluded ToVs.....	4
2.4 ToVs date	4
2.5 Direct ToVs	4
2.6 Indirect ToVs.....	4
2.7 Non-monetary ToVs.....	5
2.8 ToVs in case of partial attendances or cancellation and refund.....	5
2.9 Cross-border activities	5
2.10 R&D.....	5
2.11 Voluntary disclosure.....	5
3. Specific considerations.....	5
3.1 Country unique identifier.....	5
3.2 Self-incorporated HCP	5
3.3 Multi-year agreements	6

3.4 Country specificities.....	6
3.5 Quality Checks	6
4. Data protection legal basis	6
4.1 Consent collection	6
4.2 Legitimate interests	6
5. Form of disclosure.....	6
5.1 Date of publication.....	6
5.2 Disclosure platform	6
5.3 Disclosure language	7
6. Disclosure financial data.....	7
6.1 Currency.....	7
6.2 VAT included or excluded	7
6.3 Calculation rules	7
7. Additional Information.....	7

1. Definitions

1.1 Recipients

Healthcare professionals (HCPs) includes any registered medical practitioner, dentist, pharmacist and nurse who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

Healthcare organisation (HCO) means either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more health professionals or other relevant decision makers provide services

HCP status is determined based on the individual's role and activities at the time the Transfer of Value was made, and whether the individual is in scope under the applicable definitions.

If J&J is informed that a reportable recipient has passed away prior to publication of the disclosure, the associated ToVs are included within the aggregate section of the disclosure report for the relevant reporting period.

Patient organisation means an organisation mainly comprised of patients and/or caregivers or any user organisation such as a disability organisation, carer or relative organisation and consumer organisation that represents and/or supports the needs of patients and/or caregivers.

1.2 Kind of ToVs

The categories below describe how Transfers of Value are classified for disclosure purposes. Examples provided are illustrative and not exhaustive.

ToV Category	Included examples	Included Recipients
Collaborative Working	Improving patient pathways, service redesign.	HCOs
Donations & Grants	Funding provided to HCOs & POs to support healthcare, scientific research, or education. Grants are the provision of funds. Donations may be physical items, services, and/or benefits-in-kind.	HCOs & POs
Sponsorship (incl. events/meetings)	Conference costs, exhibition support. Corporate benefits may include symposiums, advertising space and booth space.	HCOs & POs
Contribution to Event Costs	Travel, accommodation and registration of individuals.	HCPs & POs
Contracted Services	Fees and related expenses for services such as advisory boards, speaker engagements, non-interventional studies that are retrospective in nature and patient support programmes.	HCPs, HCOs & POs
Research & Development	Clinical trials, non-clinical studies, non-interventional studies that are prospective in nature and involve the collection of patient data from or on behalf of individual, or groups of HCPs specifically for the study.	HCOs & HCPs

- ToVs through professional conference organisers (PCO) are reported either in the name of the benefitting HCO or the name of the recipient PCO.
- Research and Developments ToVs are disclosed in aggregate within the R&D category.
- Where J&J has contracted with individuals representing patient organisations to provide services, the ToV is disclosed against the Patient Organisation.

2. Disclosure's Scope

2.1 Products concerned

J&J will report all Transfers of Value in relation to prescription only medicines and will not include transfers of value that are solely related to over-the-counter medicines and medical devices.

2.2 Company concerned

Johnson & Johnson.

Janssen Sciences Ireland UC updated its brand identity in Ireland. The Company has updated its brand to unite both its pharmaceutical and MedTech segments under the Johnson & Johnson brand name.

2.3 Excluded ToVs

The following ToVs are excluded:

- ToVs solely related to OTC medicines.
- ToVs where the recipient cannot be identified (e.g., blinded market research).
- Ordinary course purchases and sales of medicines.
- Payments to medical journals or publishing companies.
- Direct costs towards food and drinks to individuals. However please note that some catering costs may have been disclosed where costs for catering have been invoiced and charged for certain activities e.g., breakfast costs with hotel room rates.
- TOVs by a distributor/sales intermediary NOT made on behalf of/at the direction of a J&J Company will be disclosed by the distributor/sales intermediary and not by the J&J Company

2.4 ToVs date

01.01.2025 – 31.12.2025.

2.5 Direct ToVs

- All payments made directly to recipients will be included in the calendar year in which J&J executed the payment or reimbursement in our financial systems.
- Out of pocket expenses paid directly to recipients are disclosed in the calendar year in which they were paid.

2.6 Indirect ToVs

- ToVs related to travel (e.g., flight and train tickets etc.), accommodation (e.g., hotel room cost), registration fees, will be included in the calendar year during which the activity/meeting took place.
 - If a Patient Organisation or individual representing a Patient Organisation performed a contracted service the related cost of travel, accommodation arrangements and any reimbursement of out-of-pocket expenses, as per the contract terms, are reported in the description of the activity.

- In cases of payments processed via a third party acting on behalf of J&J, our payment date to the third party or the payment date provided by the third party is used as the determining factor to allocate the payment to the related calendar year.

2.7 Non-monetary ToVs

J&J discloses benefits-in-kind to HCO's using the Fair Market Value stated in the contract and will be disclosed in the calendar year during which the activity took place.

J&J discloses benefits-in-kind as non-financial ToV to POs, calculated via an assessment of Fair Market Value and will be disclosed in the calendar year during which the activity took place.

2.8 ToVs in case of partial attendances or cancellation and refund

- Cancellation fees are not reported.
- ToV in case of partial attendance are disclosed. For example, if an HCP attended two of the three planned days of an event, the accommodation costs for those two days will be reported.

2.9 Cross-border activities

All European and global J&J affiliates have a duty to disclose all ToVs made to in scope recipients based in the Ireland.

2.10 R&D

Research & Development (R&D) ToVs to Irish HCPs or HCOs that have been disclosed in aggregate are related to the planning or conduct of:

1. Non-clinical studies (as defined in the OECD Principles on Good Laboratory Practice)
2. Clinical trials (as defined in EU Directive 2001/20/EC (Article 2(a)))
3. Non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual or groups of health professionals specifically for the study.

2.11 Voluntary disclosure

[N/A]

3. Specific considerations

3.1 Country unique identifier

J&J will report the recipients address in the J&J database at the time of reporting. If no current address is available within the database, J&J will disclose the address on the contract at the time the ToV took place, or the address provided at the time of registering for a given activity.

3.2 Self-incorporated HCP

- If an HCP contracts with J&J through their private limited company and if any ToV is paid to the company in place of the HCP, J&J will attribute the ToV to the individual HCP and not the private limited company.

- If an HCP contracts with J&J and the ToV is paid to the HCO that the HCP is employed by, J&J will attribute the ToV to the HCO that received the ToV and not the HCP.
- Individual expenses (e.g. travel & accommodation) will be attributed to the HCP unless stated otherwise in the contract.

3.3 Multi-year agreements

Where contracts span multiple years, each individual ToV is captured and disclosed in the corresponding year the ToV was made.

3.4 Country specificities

The link to J&J Innovative Medicine Ireland 'How we Work' can be found on the J&J public website <https://www.jnj.com/innovativemedicine/ireland/how-we-work>. The site contains information on how we work with HCPs, HCOs and POs.

3.5 Quality Checks

J&J applies proportionate internal data quality reviews in advance of disclosure of Transfers of Value. Reporting is largely system-generated and supported by reconciliation to relevant source data. In addition, targeted manual review and oversight activities are undertaken prior to publication.

4. Data protection legal basis

4.1 Consent collection

J&J discloses ToVs under legitimate interest.

4.2 Legitimate interests

J&J discloses based on legitimate interest.

- Where an HCP has objected to disclosure on an individual basis, all associated ToV will be disclosed in the aggregate section of the report.
- HCOs and POs are disclosed on an individual named basis.

5. Form of disclosure

5.1 Date of publication

30/06/2026

5.2 Disclosure platform

Healthcare Professionals, and Healthcare Organisations Disclosures	Transfer of Value – www.transferofvalue.ie
Patient Organisation Disclosures	Johnson & Johnson website: https://public.janssentransferofvalue.com/ie_en/pos-report/ . * Date of contract = Activity start date

5.3 Disclosure language

English

6. Disclosure financial data

6.1 Currency

- All values reported are in Euro (€).
- ToVs made in a currency other than Euro will be converted to Euro. Exchange rate details can be provided on a case-by-case basis.

6.2 VAT included or excluded

- Direct payments are disclosed exclusive of VAT and inclusive of withholding tax, if applicable.
- All ToVs for travel and accommodation (e.g., flight ticket, hotel room, etc.) are reported inclusive of VAT, where applicable.
- The disclosure reported ToV amounts should not be used for VAT/Tax reporting purposes. If fiscal reports are required, the company provides them directly to the recipient.

6.3 Calculation rules

J&J discloses benefits in kind using the fair market value listed in the contract between J&J and the recipient.

7. Additional Information

J&J relies on a combination of automated systems, standardised processes, and manual data entry from internal and external sources to record and report relevant ToV data.

In case of significant changes to the initial publication (e.g., objection to individual disclosure), J&J will publish an amendment within a reasonable timeframe.

Should a recipient consider that the report is incomplete or incorrect, please contact us via disclosure@janssen.co.uk. We will review the query and, where appropriate, make updates in line with applicable disclosure requirements.